The emergence of multidrug-resistant tuberculosis (MDR-TB) is one of the major threats to the control and prevention of TB in the world. 1 
"
3 MDR-TB is extremely difficult and expensive to treat and to cure. 4 ' 5 Case-fatality rates from MDR-TB are as high as 90% among people infected with human immunodeficiency virus (HIV) 6 and 22% among people without HIV infection. 5 Numerous outbreaks of MDR-TB have been reported in different settings throughout the United States (US) and the world. 6 " 18 Using molecular techniques, Bifani et al. recently documented that a single MDR-TB strain could be widely spread throughout the nation. 19 In response to the emergence of MDR-TB, the Centers for Disease Control and Prevention (CDC) organized a federal task force to develop a national action plan to combat MDR-TB. 20 ' 21 The objectives of the plan were to bring current outbreaks under control, to prevent new outbreaks and to resume progress toward the elimination of TB in the US. According to a nationwide survey conducted in the first quarter of 1991, 3 of all those with TB whose isolates were tested for drug susceptibility, 14.2% were resistant to one or more antituberculosis drugs and 3.5% were resistant to both isoniazid and rifampin (MDR-TB). The proportion of MDR-TB in New Jersey (6.6%) was ranked second highest in the nation, after New York State (12.9%). New York City accounted for 61.4% of the nation's MDR-TB cases. Because of the close proximity to New York City, New Jersey is an ideal site to study the spread of MDR-TB. The objectives of this study were to describe trends of drug-resistant TB in New Jersey from 1991 to 1995 and to investigate risk factors associated with resistance to isoniazid or rifampin or both.
Materials and Methods
Based on the recommendation of the Advisory Council for the Elimination of Tuberculosis 22 and a National MDR-TB Task Force, 21 an expanded TB surveillance system was implemented nationwide in 1993. The objective of this expanded system was to collect additional information needed to monitor the resurgence of TB and the emergence of MDR-TB in the US. Important data elements in the new TB surveillance system include: HIV infection, injecting drug and excess alcohol use within the past year, homelessness, residence at time of diagnosis (correctional/long-term care facilities), occupation, initial drug regimen, initial drug susceptibility testing, completion of chemotherapy and directly observed therapy. The New Jersey Department of Health and Senior Services fully implemented the expanded TB surveillance system in 1993, including use of the standardized national data management and transmission system (SURVS-TB) developed by CDC. 23 TB patients diagnosed in New Jersey are reported to the state health department by hospitals, laboratories and health care providers. Data on drug susceptibility testing for TB isolates were also colleaed by the state health department in 1991-1992. Annual data for 1991 are incomplete as only TB isolates reported in the first, third and fourth quarters were tested for drug susceptibility. In this study, DR-TB is defined as a TB isolate that was resistant to one or more antituberculosis drugs. MDR-TB is defined as an isolate resistant to both isoniazid and rifampin. Country of origin was defined by the US Bureau of the Census: 24 anyone bom in the US or a territory of the US, as well as anyone born in a foreign country but having at least one American parent, was defined as US-born; all others were categorized as foreign-born.
DR-TB and MDR-TB trends were analysed using 1991-1995 state surveillance data. The proportion of DR-TB and MDR-TB from 1991 to 1995 was calculated only for TB isolates tested for drug susceptibility. The extended Mantel-Haenszel procedure was performed to evaluate drug resistance trends over time. 25 People with TB (n = 1926) whose isolates were tested for drug susceptibility during 1993-1995 were included in the evaluation of risk factors. The proportion of isolates resistant to a variety of antituberculosis chemotherapeutic agents was calculated from the 1993-1995 TB surveillance data. Both univariate and multivariate logistic regressions were performed to calculate odds ratios (OR) and 95% confidence intervals (CI) for isoniazid-or rifampin-resistant TB and MDR-TB. The SAS statistical package was employed for the analysis. 26 Because a large proportion of TB cases was missing for data regarding injecting drug use, excess alcohol use and HIV infection, an unknown category was created for the univariate analysis. For HIV status, the unknown category included all TB cases who were not tested for HIV antibody or who did not know their HIV status even if previously tested. Results from univariate and multivariate analyses were not significantly different, and only univariate OR are presented in this paper.
Results

Trend of drug-resistant tuberculosis in New Jersey
From 1991 to 1995, 4582 cases of TB were identified in New Jersey ( Table 1 ). The proportions of TB cases who were bacteriologically confirmed were fairly stable from 1991 to 1995. The proportion of TB isolates tested for drug susceptibility increased from 74% in 1991 to 95% in 1995. The proportion of DR-TB and MDR-TB in Table 1 was calculated among all TB isolates tested for drug susceptibility. The proportion of DR-TB increased slightly in 1992 and remained relatively stable (-16%) in 1993-1995. The expanded TB surveillance data were used to examine the trends in resistance to the five first-line drugs against TB (Table 2) . From 1993 to 1995, the proportion of TB isolates resistant to isoniazid declined steadily from 11.8% to 9.7%. A significant decrease in the proportion of pyrazinamide resistance was observed for the same period. In contrast, there was an increase in the proportion of TB isolates resistant to ethambutol or streptomycin. It is not possible to describe the trend of resistance to second-line drugs because of the small number of isolates tested against these drugs.
Pattern of resistance to antituberculosis drugs
The 1993-1995 data obtained from the expanded TB surveillance system were combined to calculate the proportion of TB patients with isolates resistant to each of the antituberculosis drugs ( Table 3 ). The denominator of the proportion is the number of people with TB whose isolates were tested for a specific drug. Overall, 320 (16.6%) of the 1926 isolates tested were resistant to at least one of these drugs. Of the five first-line drugs, isoniazid had the highest proportion of resistance (10.6%), followed by streptomycin, rifampin, pyrazinamide and ethambutol. Of the second-line drugs, ethionamide and cydoserine also showed a high proportion of resistance. It should be noted that 3 (21.4%) of the 14 cases tested for rifabutin susceptibility were resistant. Risk factors for tuberculosis patients resistant to isoniazid or rifampin Table 4 shows the proportion of isoniazid and rifampin resistance according to the demographic faaors of patients and TB risk factors. OR and 95% CI for isoniazid-or rifampin-resistant TB associated with each of these factors are also shown in this Table. As expected, recurrent TB patients were significantly associated with increased risk of both isoniazid-resistant TB (OR = 4.5, 95% CI : 2.6-7.6) and rifampin-resistant TB (OR = 5.5, 95% CI : 2.8-11). Rifampin-resistant TB was also found to be significantly associated with HIV infection (OR = 4.0, 95% CI : 1.9-8.3) and being male (OR = 1.8, 95% CI : 1.1-3.0). Resistance to these two drugs seemed different at different age groups. Isoniazid resistance was more likely to be associated with younger age groups (<25 and 25-44 years old). Rifampin resistance had the highest level for people aged 25-44 years old (5.7%) and was rare among those aged <25 years old (0.5%). Foreign-born individuals were more likely to have isoniazid resistance than the US-bom (OR = 1.6, 95% CI : 1.2-2.1). However, there was no significant relationship between country of origin and rifampin resistance. Asians had the highest level of isoniazid resistance (15.1%). Rifampin resistance, however, was the highest in Hispanics (5.6%). Homelessness, injecting drug use and excess alcohol use were not significantly associated with resistance to either of these two drugs. Table 5 shows the proportion of MDR-TB and OR for MDR-TB associated with potential risk faaors. Like isoniazid-or rifampin-resistant TB, MDR-TB was also significantly associated with recurrent TB (OR = 6.1, 95% CI: 2.9-13). The risk of MDR-TB was significantly increased among HIV-infeaed TB patients (OR = 3.6, 95% CI : 1.5-8.8). MDR-TB was not associated with being foreign-bom (OR = 1.1, 95% CI: 0.6-1.9). Males seemed more likely to have MDR-TB than females (OR = 1.8, 95% CI: 1.0-3.3). There was no significant association between MDR-TB and race/ethnicity, homelessness, injeaing drug use and excess alcohol use.
Risk factors for multidrug-resistant tuberculosis
Discussion Trends in drug-resistant tuberculosis
This study found a 53% decrease in the proportion of MDR-TB among TB cases in New Jersey from 1991 to 1993, but no significant change from 1993 to 1995. New York City reported a 44% decrease of MDR-TB cases from 1991-1992 to 1993-1994. 27 The decline of MDR-TB in New Jersey from 1991 to 1993 is probably a result of the effeaive control of potential outbreaks of MDR-TB in hospitals and correaional facilities. In the late 1980s and early 1990s, the majority of MDR-TB cases in the US, including New Jersey, was associated with outbreaks in hospitals and correctional facilities.
6 " 14 Since 1993, no MDR-TB outbreaks have been reported in the State of New Jersey. The proportion of TB patients with isolates resistant to isoniazid or pyrazinamide has also decreased steadily in the last 3 years. The proportion of rifampin resistance declined slightly from 1994 to 1995. The success of the directly observed therapy implemented in the state since 1993 might be one of the reasons for the decline in drug resistance. Weis et al. recently reported that direaly observed therapy could significantly reduce the frequency of drug resistance. 28 In New Jersey, the number of TB patients given direaly observed therapy has increased substantially since 1991. In 1991, only a small number of TB patients were treated with direaly observed therapy in Newark (the largest city in New Jersey). In 1995, 754 TB patients/suspeas, contacts and TB/HIV reaaors were placed on direaly observed therapy statewide.
Drug resistance and implications for chemotherapy
The proportion of isoniazid-(10.6%) or rifampin-resistant TB (4.3%) in this study was slightly higher than the national averages in 1991 (9.1% and 3.9% respeaively). 3 The proportion of pyrazinamide-(3.3%), ethambutol-(1.3%) or streptomycinresistant TB (5.0%) was lower than the national averages (5.8%, 2.4% and 5.7%, respeaively). Approximately 98% of all TB cases in New Jersey were reported from counties with a proportion of isoniazid resistance greater than 4%. The high proportion of drug resistance statewide suggests that all TB patients in New Jersey should be placed on an initial four-drug regimen as recommended by the Centers for Disease Control and Prevention and American Thoracic Society. 4 ' 29 In a recent study from New York City, Telzak etal. reported that MDR-TB patients without HIV infeaion responded well to appropriate chemotherapy, both clinically and microbiologically. 30 
Recurrent tuberculosis and drug resistance
Recurrent TB was found to be the most important risk faaor for any kind of drug resistance examined in this study. TB patients who had a history of aaive TB were much more likely to have drug resistance than those who had no prior TB disease. Patient non-compliance has been well documented as the most important reason for the relapse of TB disease and the development of drug resistance. 31 " 34 Conversely, a large proportion of MDR-TB patients (83.6%) had no prior history of TB disease (Table 5 ). This suggests that the majority of the MDR-TB patients in New Jersey were infeaed in the last several years as MDR-TB was uncommon in the 1980s. A substantial proportion of the MDR-TB patients could perhaps have been prevented if source cases were treated and managed effeaively. 
HIV infection and drug resistance
The emergence of HIV infection is one of the most important reasons for the resurgence of TB in the US. 35 Burwen et al. estimated that HIV infection might account for a minimum of 30% of excess TB cases from 1985 to 1990. 36 A number of outbreaks of MDR-TB have been observed among HlV-infected people.
6 " 8 ' 10~13 This study found a strong association between HIV infection and rifampin-resistant TB and MDR-TB, but not isoniazid-resistant TB. In this study, half of the cases had unknown HIV status or had never been tested. People with unknown HIV status were more likely to be elderly (5»65 years old, 27%) than those with known HIV status (5.5%). People with unknown HIV status had an intermediate risk of MDR-TB (2.4%) when compared with HIV infeaed (4.9%) and uninfeaed (1.2%) people. After adjustment for age, sex, homelessness, injeaing drug use and excess alcohol use in a multivariate logistic model, HIV infeaion remained significantly associated with MDR-TB.
Country of origin and drug resistance
Another important reason for the resurgence of TB in the US is the increasing number of foreign-bom people with TB. 35 ' 37 Because of the unregulated market of antibiotics in some foreign countries, especially in Asia and Mexico, it is speculated that foreign-born people with TB should have a higher proportion of drug resistance than US-born people. Among the 641 foreignborn people with TB in this study, 42% were Asians and 33% Hispanic TB patients who were bom in Asia indeed had a higher proportion of isoniazid resistance (43/272 = 15.8%), but not rifampin resistance. Foreign-bom Hispanics had only a slightly higher proportion of rifampin resistance (10/212 = 4.7%), but not isoniazid resistance. In fact, there was almost no difference in the proportion of MDR-TB between foreign-born (3.7%) and US-born (3.4%) people in a nationwide survey. 3 The same results for foreign-born (3.0%) and US-born (2.8%) people were observed in this study. It is not surprising that MDR-TB was not associated with foreign-born status, because rifampin has not been used or has only been used recently in many parts of the world.
Implications of this study
This study documented a 53% decrease in the proportion of MDR-TB among people whose TB isolates were tested for drug susceptibility in New Jersey from 1991 to 1993, but no further decline from 1993 to 1995. The decline from 1991 to 1993 probably resulted from the effective control of potential outbreaks of MDR-TB in hospitals and correctional facilities. Despite the decline in MDR-TB in New Jersey, the proportion of drug resistance is still alarmingly high. An initial four-drug regimen should be encouraged for the treatment of anyone with TB in New Jersey. In addition, continuous efforts should be directed at the prevention of MDR-TB among people infected with HIV and at improving chemotherapy completion rates for everyone withTB.
